Start Consultation
Vol. 1 / Issue 1 / May 2026 GetMounjaro.co.za

The medicine that became South Africa's biggest pharmaceutical product.

Mounjaro arrived in late 2024 and reshaped the local landscape within a year. This is an editorial guide for South Africans considering it.

A Mounjaro KwikPen photographed on a textured surface in warm natural light
In Brief

What this guide covers

Tirzepatide, sold as Mounjaro, is a once weekly injection that became the highest selling pharmaceutical product in South Africa in late 2025. This guide explains what it is, who it is for, what the trial evidence shows, and how to think about it as a treatment option.

#1
SA pharmaceutical product by sales (Nov 2025, IQVIA)
52%
GLP-1 market share at end Jan 2026
~20%
Mean weight reduction at max dose in trials
R1.3bn
Forecast SA sales in year through June 2026
From The Issue

Features

Long form analysis on what Mounjaro is, how it works, what the evidence actually shows, and what its arrival means for South African patients.

Reference

The Practical Reading

If you have already decided to consult about Mounjaro, these are the pages that answer the actual questions.

For Readers

If you are considering Mounjaro, the next step is a consultation.

Ten minutes online. Reviewed by a registered SA doctor. Prescription emailed if appropriate.

Start A Consultation